Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADRX: Andrx Corporation -- Ignore unavailable to you. Want to Upgrade?

To: mact who wrote (6)	4/18/2002 3:35:34 PM
From: Dolfan	Respond to of 14

Interesting: 11:56AM Andrx: Goldman Sachs says latest trial news is positive (ADRX) 41.36 +2.85: Goldman Sachs views the latest news from the ADRX-AZN Prilosec patent trial as positive for ADRX; the judge cited AZN's "utter failure to provide ADRX with full and adequate discovery" and ordered AZN to provide complete information and advise both ADRX and the court of its progress on a daily basis. Firm believes that the '281 patent could now be at risk of invalidity and unenforceability due to "inequitable conduct." Firm is also optimistic that a favorable Stage III interim ruling on the trial could come next week. Price target for ADRX is either $110 (with generic Prilosec) or $38 (without).